Magdalena holds an MSc in Pharmaceutical Bioscience and an interdisciplinary PhD merging the fields of psychiatry, immunology and neuropharmacology. Her previous research focused on metabolic and immunologic changes in psychotic disorders. She is now focusing on science writing, allowing her to culture her passion for medical science and human health.
Evidence suggesting that bardoxolone methyl can delay kidney failure has surfaced in a re-analysis of data from a clinical trial in diabetics that was terminated over safety concerns, Reata Pharmaceuticals reports. The ... Read more
Researchers report that mutations in kidney genes not involved in collagen production may worsen the severity of Alport syndrome. The study may provide an explanation as to why Alport patients ... Read more
Women with X-linked Alport syndrome may develop severe disease progression. But the type of mutation a patient carries does not predict the disease’s severity, and physicians should pay careful attention ... Read more
Billy Hudson, PhD, a researcher focusing on the Alport syndrome-associated collagen 4, has been awarded the 2018 Distinguished Investigator Prize by the International Society for Matrix Biology. The prize will ... Read more
Regulus Therapeutics and Sanofi-Genzyme are among companies working on Alport syndrome therapies that can block RNA molecules’ actions. RG-012 is a man-made version of naturally occurring oligonucleotides, or RNA molecules that help regulate gene ... Read more
Retinal thickness may be used to distinguish men with X-linked Alport syndrome from those with a similar but much more benign kidney disease known as thin basement membrane nephropathy, a ... Read more
Australian researchers have identified a protein that is a possible biomarker of the progression of Alport syndrome and similar kidney diseases. They detected higher than normal levels of the protein ... Read more